Soluble receptor for advanced glycation end products independently predicts cardiometabolic syndrome in Latino youth

Pediatric Diabetes

Volumn 15, Issue 6, 2014, Pages 403-407

  Brickey, Sarah R ^a   Ryder, Justin R ^b   Mcclellan, Donald R ^a   Shaibi, Gabriel Q ^a,b,c,d  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Metabolic syndrome; sRAGE; Youth

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADOLESCENT; ARTICLE; CARDIOMETABOLIC RISK; CARDIOMETABOLIC SYNDROME; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISPANIC; HUMAN; INSULIN RESISTANCE; JUVENILE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC DISORDER; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ADULT; BLOOD; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; ETHNOLOGY; METABOLIC SYNDROME X; PROGNOSIS; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ARIZONA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HISPANIC AMERICANS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 84906791460     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12095     Document Type: Article

References (26)

1. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999: 22: 1543-1548.
2. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004: 63: 582-592.
3. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation end products (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009: 11: e9.
4. Basta G, Sironi AM, Lazzerini G et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006: 91: 4628-4634.
5. Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002: 106: 2827-2835.
6. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation end products (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005: 25: 879-882.
7. Shaibi GQ, Coletta DK, Vital V, Mandarino LJ. The design and conduct of a community-based registry and biorepository: a focus on cardiometabolic health in Latinos. Clin Transl Sci 2013 [Epub ahead of print].
8. Eisenmann JC, Laurson KR, DuBose KD, Smith BK, Donnelly JE. Construct validity of a continuous metabolic syndrome score in children. Diabetol Metab Syndr 2010: 2: 8.
9. Eisenmann JC. On the use of a continuous metabolic syndrome score in pediatric research. Cardiovasc Diabetol 2008: 7: 17.
10. Wijndaele K, Beunen G, Duvigneaud N et al. A continuous metabolic syndrome risk score: utility for epidemiological analyses. Diabetes Care 2006: 29: 2329.
11. Franks PW, Olsson T. Metabolic syndrome and early death: getting to the heart of the problem. Hypertension 2007: 49: 10-12.
12. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002: 106: 3143.
13. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011: 1243: 88-102.
14. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007: 13: 625-635.
15. Devangelio E, Santilli F, Formoso G et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007: 43: 511-518.
16. Sebekova K, Somoza V, Jarcuskova M, Heidland A, Podracka L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009: 4: 112-118.
17. Chiavaroli V, D'Adamo E, Giannini C et al. Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care 2012: 35: 1361-1363.
18. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008: 359: 61-73.
19. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999: 103: 1175-1182.
20. de Giorgis T, D'Adamo E, Giannini C et al. Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? Antioxid Redox Signal 2012: 17: 187-191.
21. Amin MN, Mosa AA, El-Shishtawy MM. Clinical study of advanced glycation end products in Egyptian diabetic obese and non-obese patients. Int J Biomed Sci 2011: 7: 191-200.
22. Falcone C, Emanuele E, D'Angelo A et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005: 25: 1032-1037.
23. Colhoun HM, Betteridge DJ, Durrington P et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011: 60: 2379-2385.
24. Stovitz SD, Schwimmer JB, Martinez H, Story MT. Pediatric obesity: the unique issues in Latino-American male youth. Am J Prev Med 2008: 34: 153-160.
25. Kelly LA, Lane CJ, Weigensberg MJ, Toledo-Corral CM, Goran MI. Pubertal changes of insulin sensitivity, acute insulin response, and beta-cell function in overweight Latino youth. J Pediatr 2011: 158: 442-446.
26. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004: 89: 108-113.